Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 科凌生物医疗有限公司
- Publication Date
- 2016-10-26
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The present invention relates to the fields of biology, immunology, medicine and cancer treatment, in particular to the therapy for myeloid proliferative disorder or lymphoid tissue proliferative disorder. More specifically, the invention relates to antibodies against acute myeloid leukemia cells. Background technique
[0002] Acute myelogenous leukemia (AML) is a high-risk malignant tumor, and the five-year survival rate of patients younger than 60 years is 40% to 50%. The prognosis for patients over 65 years is even worse, with less than 20% of patients achieving sustained remission. Allogeneic stem cell transplantation is often used in the treatment of acute leukemia. It was originally designed to rescue patients from otherwise fatal myeloablative chemotherapy, but was subsequently found to be complicated by complications related to the alloreactive immune response (graft versus host disease; GvHD). T-cell depletion of the graft prior to reinfusi...